Enliven Therapeutics, Inc. Common Stock (ELVN) Stock Price
ELVNStock
$57.86+184.18%52W
Market Cap$4.24B
P/E—
PEG Ratio—
Div yield—
Beta0.46
ELVN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)92.38%
Price vs S&P 500 (4W)-1.85%
VGM Score78.58
ELVN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.38 | -$0.49 | -29.80%(-$0.11) | |
| Q1 2026 | -$0.41 | -$0.38 | +7.32%(+$0.03) | |
| Q4 2025 | -$0.47 | -$0.48 | -1.05%(-$0.01) | |
| Q3 2025 | -$0.47 | -$0.32 | +31.18%(+$0.15) | |
| Q2 2025 | -$0.42 | -$0.49 | -16.67%(-$0.07) |
ELVN Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.25
4.29
4.33
4.33
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ELVNEnliven Therapeutics, Inc. Common Stock | — | — | B | $57.86 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Enliven Therapeutics, Inc. Common Stock
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule targeted therapies for cancer. Its pipeline includes ELVN-001, which targets BCR-ABL fusion in chronic myeloid leukemia, and ELVN-002, a HER2 inhibitor designed to address both wild-type and mutant forms of the protein.